Docosanol
- Generic Name
- Docosanol
- Brand Names
- Abreva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H46O
- CAS Number
- 661-19-8
- Unique Ingredient Identifier
- 9G1OE216XY
- Background
Docosanol is a drug used for topical treatment for recurrent herpes simplex labialis episodes (episodes of cold sores or fever blisters). A saturated 22-carbon aliphatic alcohol, docosanol exhibits antiviral activity against many lipid enveloped viruses including herpes simplex virus (HSV). Docosanol inhibits fusion between the plasma membrane and the herpes simplex virus (HSV) envelope, thereby preventing viral entry into cells and subsequent viral replication.
- Indication
For the topical treatment of recurrent oral-facial herpes simplex episodes (cold sores or fever blisters).
- Associated Conditions
- Cold Sore
Efficacy and Safety of Acyclovir-penciclovir Cream Versus an Abreva in the Suppression of Herpes Simplex Virus Eruptions
- First Posted Date
- 2024-08-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 40
- Registration Number
- NCT06558838
- Locations
- 🇺🇸
University of Utah MidValley Dermatology, Murray, Utah, United States
EDTA Eye Drops Compared to Abreva for Herpes Simplex Virus Eruptions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 20
- Registration Number
- NCT04893577
- Locations
- 🇺🇸
University of Utah MidValley Dermatology, Murray, Utah, United States
An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2020-09-07
- Lead Sponsor
- Laboratoire Boreaderme Inc.
- Target Recruit Count
- 164
- Registration Number
- NCT03977792
Comparison of Topical Antiviral Agents for Labial Cold Sores (Herpes Labialis)
- Conditions
- Reccurent Herpes Labialis
- First Posted Date
- 2007-05-01
- Last Posted Date
- 2007-05-01
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 75
- Registration Number
- NCT00467662
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.